Page 204 - ebook HCC

GENEV
PROGRAMME AND ABSTRACTSAND ABSTRACTS
EASL
202 PROGRAMME GENEVA, SWITZERLANDA, SWITZERLAND EASL HCC SUMMITHCC SUMMIT 203
202
203
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C6
INFLUENCE OF SARCOPENIA IN SORAFENIB
DISCONTINUATION DURING ADVANCED
HEPATOCARCINOMA TREATMENT

Elia Gigante , Sara Gallina , Ilaria Deli , Francesco Carbonetti , Elsa Iannicelli , Results: Patients were mainly males (84%), etiology of liver disease was HCV in 31%,
1
1
2
2
1
Gianfranco Delle Fave , Massimo Marignani 1 alcohol in 23%, NASH in 23%, mixed in 15% and other causes in the remaining 8%. In our
1
1 Digestive and Liver Diseases, Radiology, School of Medicine and Psychology study 23% of the patients (3/13) was non-sarcopenic and 77% (10/13) was sarcopenic.
2
University “Sapienza”, S. Andrea Hospital, Rome, Italy The two groups had similar baseline characteristics: age was 63 vs 65 years (P= 0,78),
albumin level was 3,29 vs 3,18 gr/dl (P= 0,70), total proteins were 6,73 vs 6,75 gr/dl
Corresponding author’s e-mail: elia.gigante@hotmail.it (P= 0,70), international normalized ratio (INR) was 1,33 vs 1,22 (P= 0,369), BMI was 25
vs 23,3 (P= 0,419). There was no statistically significant difference in number of days
on treatment before discontinuation in the two groups (P= 0,5), with an overall time in
Introduction: Sarcopenia is a condition characterized by muscle wasting, it has been treatment of 92 days. Interestingly the most common reason of interruption was the
associated with poor outcomes in patients affected by cirrhosis and solid tumors, and with occurrence of an adverse event 69% (9/13) compared to progression of HCC 31% (4/13)
a higher rate of toxicity during chemotherapy. Sorafenib is the most widespread treatment without difference between the two groups (P= 1). The most common adverse events were
for advanced hepatocarcinoma (HCC). Little is known about the influence of sarcopenia bleeding and diarrhea (grade 2-4) respectively in 15% and in 31% of the patients.
on Sorafenib treatment.
Conclusions: Sarcopenia is present with high prevalence in patients affected by advanced
Aims: To analyze the tolerance of sorafenib treatment in sarcopenic cirrhotic patients HCC. In our cohort sarcopenic patients were not associated with a higher rate of toxicity
compared to non-sarcopenic ones. nor with shorter period of treatment compared to non sarcopenic.
Methodology: We conducted a preliminary retrospective study on 13 consecutive patients
from a single centre affected by advanced hepatocarcinoma and treated with sorafenib that
stopped the medication. Before treatment a computed tomography scan was performed
and skeletal muscle cross-sectional area was calculated. A transverse CT image with a
multiplanar reconstruction (MPR) from L3 was collected from each scan. Images were
analyzed manually marking the muscles areas identified by Hounsfield unit thresholds of
CLINICAL POSTER ABSTRACTS height. Limits for sarcopenia were considered 38.5 cm2/m2 for women and 52.4 cm2/m2 CLINICAL POSTER ABSTRACTS
29 to 150.23 and then summed. The Cross-sectional areas were subsequently normalized
for height obtaining the skeletal muscle index, expressed as cross-sectional muscle area/

for men.